Peter J. Hotez, M.D., Ph.D., is the Baker Institute fellow in disease and poverty. He is dean of the National School of Tropical Medicine and professor of pediatrics and molecular virology and microbiology at Baylor College of Medicine, where he is also chief of the Section of Pediatric Tropical Medicine and the Texas Children’s Hospital Endowed Chair of Tropical Pediatrics.
Hotez is an internationally recognized physician-scientist with expertise in neglected tropical diseases and vaccine development. He leads the only product development partnership for developing new vaccines for hookworm, schistosomiasis and Chagas disease.
He is the author of more than 400 original papers and the acclaimed book “Forgotten People, Forgotten Diseases” (ASM Press). Hotez previously served as president of the American Society of Tropical Medicine and Hygiene and as founding editor-in-chief of PLoS Neglected Tropical Diseases. He is an elected member of the Institute of Medicine (IOM) of the National Academy of Sciences. In 2011, he was awarded the Abraham Horwitz Award for Excellence in Leadership in Inter-American Health by the Pan American Health Organization of the World Health Organization. In 2015, the White House and U.S. State Department selected Hotez as a United States science envoy. He obtained his undergraduate degree in molecular biophysics from Yale University in 1980 (Phi Beta Kappa), followed by a Ph.D. in biochemical parasitology from Rockefeller University in 1986 and an M.D. from Weil Cornell Medical College in 1987.
Contact him at email@example.com or (713) 798-1199.
The new omicron booster shot protects against the COVID-19 subvariant that’s currently prevalent in Texas and the United States. “The key is to be mindful of your own vaccination situation and keep up with your boosters," Dr. Peter Hotez, the Baker Institute fellow in disease and poverty, told Texas Standard. You should be able to get the new one — and you shouldn’t wait, he added.
Developed by fellow Dr. Peter Hotez and Maria Elena Bottazzi, Corbevax has now been administered to 70 million adolescents in India. This low-cost, easy-to-make, and patent-free COVID-19 vaccine was recently authorized for use as a booster in adults.
"The best way to ensure you won't become infected is to get vaccinated," said Dr. Peter Hotez, the Baker Institute fellow in disease and poverty. "Monkeypox, although rarely fatal, is a serious and debilitating infectious disease, and could require hospitalization."